SEC Form 4 · accession 0001193805-15-000402

ADMA BIOLOGICS, INC. · ADMA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Mar 16, 2015

Accepted (ET)

Mar 18, 2015 · 9:59 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001368514

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock, $0.0001 par value per share^F1,F2,F3,F4	Mar 16, 2015	P	1,200	$7.9979	A	577,574	I	Please see footnote
Common Stock, $0.0001 par value per share^F2,F5,F4	Mar 17, 2015	P	500	$8.0086	A	578,074	I	Please see footnote

No Table II lines on this filing.

F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.9850 to $8.0086 per share. The reporting person undertakes to provide to ADMA Biologics, Inc., any security holder of ADMA Biologics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased by it at each separate price on March 16, 2015.
F2528,016 of these shares are held by Maggro, LLC, an entity for which Jerrold Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
F337,794 of these shares are held by the Genesis Foundation, an entity for which Jerrold Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
F4These shares are being purchased by the Genesis Foundation, an entity for which Jerrold Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.
F538,294 of these shares are held by the Genesis Foundation, an entity for which Jerrold Grossman has the power to vote and dispose of the shares of common stock of ADMA Biologics, Inc.